Manchester, UK, September 3 2012 – Conformetrix Ltd, a leader in optimising drug
discovery and design, will be presenting at ELRIG Drug Discovery 20121
on September 6 2012. The presentation, 'The application of ligand conformational
preferences in drug discovery', will discuss how the tuning of conformational
preferences can be used to optimise the potency of drug candidates.
As well as insights from Conformetrix's proprietary preclinical drug discovery
programmes, Senior Medicinal Chemist Barrie Martin will discuss projects in which
the dynamic 3D-structures of two drug molecules were solved.
Conformetrix’s NMR technology determines accurate three-dimensional structures -
or conformations - of drug molecules in their bioactive states. This is achieved
without the need for traditional structural information regarding the protein target of
each drug and provides researchers with valuable information on how development-
stage compounds are likely to interact with their targets. This new information should
improve the efficiency and quality of the lead identification, lead optimisation and
candidate selection stages of drug discovery programmes.
1 ELRIG/SLAS Drug Discovery 2012, September 5-6 2012, Manchester, UK, www.elrig.org
For further information please contact:
Sam Williams, CEO +44 (0)7881 588947
Emma Palmer Foster, Strategic Communications Consultant +44 (0)7880 787185
About Conformetrix Ltd
Conformetrix is a Manchester, UK-based company focused on optimising drug discovery
and design. It was founded in 2008 as a spin-out from the University of Manchester. The
company uses its NMR-based technology to solve the dynamic 3D structures of a broad
range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. Since Conformetrix's NMR technology shows what shapes molecules adopt when they are
active, it provides high-quality templates for drug discovery and design, and valuable
information for drug candidate optimisation. In addition, the data is generated faster and
more cheaply than by standard techniques such as X-ray crystallography. Conformetrix has
solved structures for several large pharmaceutical companies, as well as developing
proprietary drug programmes, and recently signed a collaboration with AstraZeneca. It has
been funded since inception by specialist life science investor Aquarius Equity Partners. For
more information, please go to www.conformetrix.com.